AppliedVR Raises $36 Million Series B

To Scale Comprehensive Virtual Reality Platform For Healthcare

AppliedVR, a pioneer advancing the next generation of immersive therapeutics, today announced $36 million in series B funding, bringing its total funding to $71 million. The round, which included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures, set up AppliedVR for rapid growth as it prepares for its decision from the FDA on its first de novo submission.

Virtual reality provides an immersive experience that has been proven to improve the lives of people experiencing pain. The AppliedVR platform comprehensively addresses multiple pain indicators, leading to people reporting reductions in pain and associated interference of daily life both immediately and for several months after treatment is completed. People suffering from pain follow a science-backed, clinically validated curriculum of immersive VR programming to reduce their pain and help them learn skills for managing pain in the real world.

“For too long, we’ve relied on the notion that people need to take pills or rely on surgery to feel better and lead a better quality of life. At AppliedVR, we’re building an unparalleled body of evidence for providers and payers to demonstrate that immersive therapeutics can fill the massive unmet need for patients who are frustrated by current treatment paradigms. And, we are starting with chronic pain, one of the most complex, costly conditions,” said Matthew Stoudt, co-founder and CEO of AppliedVR. “Our goal is to make immersive therapeutics accessible to everyone, and this funding will help further expand our body of evidence, infrastructure and distribution platform, enabling patients and providers to take advantage of this next-generation therapeutic — while also bringing down costs for payers.”

AppliedVR’s flagship product for chronic pain recently became the first virtual reality (VR) prescription therapeutic to receive FDA Breakthrough Device Designation for treatment-resistant fibromyalgia and chronic intractable lower back pain.

“Virtual reality is now a smart, practical and effective therapy for healthcare because of innovations from companies like AppliedVR. As the pandemic demonstrated, the U.S. healthcare system desperately needs more care access through scalable solutions that are available in people’s homes, and potent therapeutics delivered with VR are a perfect solution,” said Zack Lynch, co-founder and Managing Director of JAZZ Venture Partners. “As the market leader in developing virtual reality-based prescription digital therapies, we are delighted to be backing such an exceptional team at AppliedVR.”

Whether used in clinical settings or by patients on themselves at home, AppliedVR is building an unparalleled body of evidence that demonstrates its immersive therapeutics are effective and usable for patients, scalable for providers and viable for payer reimbursement. In February, AppliedVR released results from its pivotal eight-week randomized clinical trial that found the EaseVRx device produced “clinically meaningful” improvement in multiple pain outcomes and had high participant satisfaction and engagement.

The company also just announced results from a peer-reviewed, collaborative research project with S.O.L.V.E. Health Tech, a health equity incubation partner, embedded within the University of California, San Francisco. The research, published in the Journal for Medical of Internet Research (JMIR), studied how VR could be used for pain management in safety-net settings for vulnerable populations like Medicaid patients.

Pain, especially chronic pain, is one of the most complex and expensive health problems to address. Affecting approximately one-third of all Americans1, chronic pain is estimated2 to cost as high as $635 billion each year, making it more expensive than cancer, heart disease and diabetes combined. Additionally, exacerbated by Covid-19, the chronic pain epidemic continues to fuel America’s opioid crisis, which has decimated communities and compounded the healthcare cost problem. AppliedVR is currently collaborating with Geisinger and Cleveland Clinic to advance separate NIDA-funding clinical trials that test VR as an opioid-sparing tool for acute and chronic pain.

AppliedVR is already trusted by more than 200 of the world’s leading health systems and the technology has been used by more than 60,000 patients to date in pain management and wellness programs. After today’s investment, the company will prepare for EaseVRx’s full market launch after FDA approval, finish additional payer pilots, build out its product pipeline, conduct more clinical research, and continue building its VR pharmacy platform.

SourceAppliedVR
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version